ARTICLE | Clinical News
Brilacidin-OM: Phase II start
November 24, 2014 8:00 AM UTC
Next month, Cellceutix will begin a double-blind, placebo-controlled, U.S. Phase II trial of once-daily Brilacidin-OM for 7 days in patients with head and neck cancer receiving chemotherapy and radiot...